Loading cancer entity…
Loading cancer entity…
Clinical trials
8,119 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,289)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | completed | Phase 1 / Phase 2 | 17 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05032820 | Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma | completed | Phase 2 | 40 | Medical College of WisconsinOTHER | 1 | May 19, 2026 | clinicaltrials |
| NCT02362997 |
| Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL |
| completed |
| Phase 2 |
| 82 |
| Dana-Farber Cancer InstituteOTHER |
| 1 |
| May 18, 2026 |
| clinicaltrials |
| NCT01053949 | IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma(IFM2009-02) | completed | Phase 2 | 84 | University Hospital, LilleOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT01222286 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma(KIRMONO) | completed | Phase 2 | 30 | Innate PharmaINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT01009840 | IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | completed | Phase 2 | 30 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT05169658 | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | University of WashingtonOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT01208896 | Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma(RITALLO) | completed | Phase 2 | 32 | University Hospital, BordeauxOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03413800 | Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant | completed | Phase 2 | 10 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT03927105 | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | completed | Phase 2 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05532722 | ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | completed | Phase 1 / Phase 2 | 21 | Abcuro, Inc.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03477539 | Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma | completed | Phase 2 | 49 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma(DREAMM 14) | completed | Phase 2 | 177 | GlaxoSmithKlineINDUSTRY | 18 | May 5, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 43 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT03902184 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma(TELLOMAK) | completed | Phase 2 | 170 | Innate PharmaINDUSTRY | 8 | Apr 29, 2026 | clinicaltrials |
| NCT05388123 | Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | completed | Phase 2 | 15 | Scripps HealthOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT02316106 | A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma | completed | Phase 2 | 123 | Janssen Research & Development, LLCINDUSTRY | 11 | Apr 23, 2026 | clinicaltrials |
| NCT02433795 | Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) | completed | Phase 2 | 27 | Seoul National University HospitalOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT01816971 | Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 2 | 76 | University of ChicagoOTHER | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03213678 | Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 2 | Apr 21, 2026 | clinicaltrials |
| NCT03623373 | Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 13 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT03341520 | Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma(GAZAI) | completed | Phase 2 | 89 | Heidelberg UniversityOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT02719613 | Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab | completed | Phase 2 | 67 | Bristol-Myers SquibbINDUSTRY | 13 | Apr 15, 2026 | clinicaltrials |
| NCT03213665 | Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 2 | Apr 13, 2026 | clinicaltrials |
| NCT04433156 | VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma | completed | Phase 2 | 26 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 9, 2026 | clinicaltrials |
| NCT01241734 | Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL(RICER) | completed | Phase 1 / Phase 2 | 18 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01453101 | Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma(Flu-Mel-Vel) | completed | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT02405364 | Front-line Therapy With Carfilzomib, Lenalidomide, and Dexamethasone Induction(IFM-CRd) | completed | Phase 2 | 46 | University Hospital, ToulouseOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT01679119 | Treatment of Patients With Diffuse Large B Cell Lymphoma Who Are Not Suitable for Anthracycline Containing Chemotherapy(INCA) | completed | Phase 2 | 129 | University College, LondonOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02302495 | Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma(IFM2012-03) | completed | Phase 2 | 32 | University Hospital, LilleOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT02626481 | Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma(IFM2014-04) | completed | Phase 2 | 64 | University Hospital, LilleOTHER | 2 | Apr 7, 2026 | clinicaltrials |
| NCT01067287 | Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation | completed | Phase 2 | 35 | Beth Israel Deaconess Medical CenterOTHER | 2 | Apr 6, 2026 | clinicaltrials |
| NCT02518555 | Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 2 | 42 | Jennifer WoyachOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT01502085 | Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens(RZD) | completed | Phase 1 / Phase 2 | 25 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT01813227 | A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531 | completed | Phase 2 | 7 | Hackensack Meridian HealthOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT03526250 | Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 23 | National Cancer Institute (NCI)NIH | 2 | Apr 3, 2026 | clinicaltrials |
| NCT04673617 | AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 45 | Artiva Biotherapeutics, Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06492304 | A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed/Refractory Hematologic Malignancies | completed | Phase 1 / Phase 2 | 12 | CRISPR TherapeuticsINDUSTRY | 2 | Apr 3, 2026 | clinicaltrials |
| NCT01242267 | Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT(Thal/Mel/Vel) | completed | Phase 1 / Phase 2 | 29 | Hackensack Meridian HealthOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05068440 | Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib | completed | Phase 2 | 65 | BeiGeneINDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07493486 | IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study | completed | Phase 2 | 31 | Zhejiang Cancer HospitalOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04661943 | Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma | completed | Phase 2 | 30 | Ou Bai, MD/PHDOTHER | 1 | Mar 24, 2026 | clinicaltrials |
| NCT01315132 | A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies | completed | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT02601313 | Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)(ZUMA-2) | completed | Phase 2 | 105 | Kite, A Gilead CompanyINDUSTRY | 4 | Mar 18, 2026 | clinicaltrials |
| NCT03441958 | ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma | completed | Phase 1 / Phase 2 | 19 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Mar 18, 2026 | clinicaltrials |
Data updated 22 days agoSource updated May 22, 2026source: clinicaltrials